Danaher (NYSE:DHR) Cut to “Hold” at StockNews.com

StockNews.com downgraded shares of Danaher (NYSE:DHR) from a buy rating to a hold rating in a research report report published on Saturday.

DHR has been the subject of several other reports. KeyCorp boosted their price target on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. TD Cowen boosted their target price on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Royal Bank of Canada dropped their price objective on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Stephens reissued an “overweight” rating and issued a $315.00 price objective on shares of Danaher in a report on Wednesday, October 23rd. Finally, Stifel Nicolaus raised their target price on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday, October 23rd. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus target price of $287.95.

Danaher Trading Down 0.2 %

Shares of Danaher stock opened at $234.36 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The business has a fifty day simple moving average of $246.23 and a two-hundred day simple moving average of $257.30. Danaher has a 1 year low of $222.53 and a 1 year high of $281.70. The company has a market capitalization of $169.27 billion, a price-to-earnings ratio of 44.72, a P/E/G ratio of 4.33 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. Danaher’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter last year, the company posted $2.02 EPS. Research analysts forecast that Danaher will post 7.5 EPS for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.46%. Danaher’s payout ratio is presently 20.61%.

Institutional Trading of Danaher

A number of hedge funds have recently made changes to their positions in DHR. CarsonAllaria Wealth Management Ltd. acquired a new stake in Danaher during the 2nd quarter worth approximately $25,000. nVerses Capital LLC bought a new position in shares of Danaher during the second quarter valued at $25,000. Teachers Insurance & Annuity Association of America acquired a new position in shares of Danaher during the third quarter worth $39,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Danaher in the third quarter worth $40,000. Finally, FSA Wealth Management LLC acquired a new stake in Danaher in the third quarter valued at $50,000. 79.05% of the stock is owned by institutional investors and hedge funds.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.